Special Issue

Gene Editing and Delivery for Cancer Therapy

Message from the Guest Editors

Gene therapy has potential in the treatment of human cancers. However, it has only achieved little success in clinical practice due to a lack of efficient in vivo gene editing and delivery systems. Therefore, revolutionizing new technologies in gene editing and engineering gene delivery systems that specifically target the neoplastic tissue are critical to overcoming current limitations in gene therapy. For this purpose, biodegradable lipid, polymer, and inorganic nanomaterials have been extensively explored as delivery vehicles for siRNA, mRNA, antisense oligonucleotides, CRISPR/Cas9, and more, holding great promises in improving gene silencing and genome editing in cancer tissues. Other such tools include oncolytic viruses, DNA/RNA nanostructures, therapeutic peptides and exosomes. Despite the tremendous advancements, gene therapy remains multiple obstacles before successful clinical translation. Thus, this Special Issue seeks research papers and review articles that focus on novel design and applications of gene editing and delivery that can overcome one or several significant barriers limiting the successful translation of gene therapy in cancer treatment.

Guest Editors

Dr. Yong Teng

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA

Dr. Yamin Li

Department of Pharmacology, SUNY Upstate Medicial University, Syracuse, NY 13210, USA

Deadline for manuscript submissions

closed (5 July 2023)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/109731

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)